OBJECTIVE: To analyze the effect of two different b b 3 -adrenoceptor agonists, ZD7114 and ZD2079 on 24 h energy expenditure (EE) and substrate oxidations in obese weight-stable subjects. DESIGN: Measurements of 24 h EE in a respiration chamber, before and after 14 days of treatment with one of the two b b 3 -agonists or placebo during weight maintenance. SUBJECTS: ZD7114 study: 7 male and 15 female subjects, body mass index (BMI) 28 ± 39 kgam 2 , age 27 ± 64 y; ZD2079 study: 10 male and 7 female subjects, BMI 27 ± 39 kgam 2 , age 31 ± 60 y. MEASUREMENTS: EE was measured by indirect calorimetry, spontaneous physical activity (SPA) assessed by microwave radar, and 24 h heart rate was registered by telemetry. Serum potassium was measured to test for possible b b 2 -adrenoceptor activity. RESULTS: No effects of ZD7114 were found on tested parameters whereas there was a trend for a stimulatory effect of ZD2079 on 24 h EE (day 14-pretreatment; ZD2079 vs placebo: 0.4 AE 1.1 vs 7 2.0 AE 0.4%, P 0.06) and on SPA (day 14-pretreatment; ZD2079 vs placebo: 3.4 AE 4.5 vs 7 7.7 AE 2.7%, P 0.05). However, average 24 h heart rate decreased from 77.5 AE 3.2 to 73.8 AE 2.6 min 71 from pre-treatment to day 14 with placebo but remained the same with ZD2079 (P 0.03). The latter suggests some b b 1 -adrenoceptor activity of the compound. CONCLUSION: The lack of thermogenic response with ZD7114 and the very small and questionable response with ZD2079 probably demonstrate a lack of consistency between species in the responsiveness to b b 3 -stimulation or a diversity in structure of the b b 3 receptor since both compounds have proven markedly selective thermogenic b b 3 -properties in rodents.
Introduction
Sympathomimetic agents are widely used in the treatment of obesity due to their anorectic and thermogenic potential. However, the use of unselective badrenoceptor compounds is frequently associated with adverse reactions such as palpitations and tremor attributable to b 1 and b 2 stimulation, respectively. Recently, a breakthrough may have occurred in the development of b-agonists without these common side-effects by the discovery of an atypical b-receptor, which now is designated as the b 3 -receptor. This receptor may mediate the thermogenic response to particular b-adrenergic agents. Initially, the receptor was characterized as a selective mediator of the lipolytic response to noradrenaline of brown adipocytes from rats. 1 When given to mice, compounds which are selective agonists for the rodent b 3 -receptor elicit a marked thermogenic response and when they are administered over some weeks they diminish weight gain accompanied by a profound increase in the mitrochondrial protein content of brown adipose tissue. 1 A b-receptor with ligand-binding properties similar to the rat b 3 -receptor has also been characterized in humans and this receptor is probably responsible for a great part of the lipolytic response to noradrenaline. 2 Furthermore, a human experiment has provided indirect evidence that an acute thermic effect can be mediated by an atypical b-receptor. 3 In that study, 43% of the thermogenic effect of ephedrine, a compound which potentiates the synaptic release of noradrenaline, remained after pre-treatment with the b 1 -and b 2 -antagonist nadolol. Likewise, an acute thermogenic effect of BRL 35135, which is very ef®cient on the cloned human b 3 -receptor, could not be totally abolished by blockade of the b 1 -and b 2 -receptors. 4 These ®ndings suggest that EE may be increased acutely by b 3 -stimulation in large adult mammals, a response which is unlikely to be dependent on brown adipose tissue. The present paper reports two indirect calorimetry studies which test two different b-agonists, ZD7114 and ZD2079, in obese humans. If the thermogenic effect of b 3 -adrenoceptor stimulation is related to acute or long-term activation of the adipose tissue for instance by the augmentation of lipolysis or by inducing the white adipocytes to acquire some of the properties of brown adipocytes, the increase in EE may be more marked in obese individuals. However, a similar increase in basal metabolic rate (BMR) after Ro 16-8414 has previously been found in obese and lean subjects. 5 Both compounds tested in the present study have shown a thermogenic effect on different other mammalian species (Holloway et al and unpublished results). In both studies reported in the present paper energy expenditure (EE) was measured immediately after the ®rst dose and after 14 days of continued treatment with the compound.
Methods
In both studies EE and substrate oxidation rates were determined by indirect calorimetry in respiration chambers. The studies consisted of a baseline 24 h measurement (9 am to 9 am) and a measurement with an identical protocol on the 14th day of treatment with the b-agonist or placebo. At the baseline visit the measurements were continued for another 4 h after the subjects had had their ®rst medication to evaluate a possible acute effect of the compound. To investigate a possible drug effect on sleeping EE we de®ned a particular measuring period from 1 am to 6 am Both studies were performed in a double-blind placebocontrolled design.
Indirect calorimetry measurements
EE and substrate oxidations were measured in an open-circuit respiration chamber with a¯oor area of 6.5 m 2 and a volume of 14.7 m 3 which has been described in detail previously. 7 The room temperature was maintained at 24 C during the day-time, and at 18 C at night. The oxygen and carbon dioxide exchange by the subject were determined by measurements of oxygen (Magnos 4 G, Hartman and Braun analyzer, Frankfurt, Germany) and carbon dioxide (Uras 3 G, Hartman and Braun analyzer, Frankfurt, Germany) concentrations at the outlet of the chamber and from the¯ow of the outgoing air determined by the differential pressure principle. All urine was collected for each prede®ned measuring period (except for the night where only one collection was performed) to estimate protein oxidation by assessing nitrogen excretion (urinary nitrogen concentration was measured by NA 1500, Carlo Erba Strumentazione, Milan, Italy). Protein oxidation was calculated by the assumption that 6.25 g protein was combusted per gramme of nitrogen excreted. Subsequently, non-protein oxygen and carbon dioxide exchanges were calculated by the assumption that 0.957 l oxygen is consumed and 0.774 l carbon dioxide is produced per gramme of protein being oxidized. Carbohydrate and fat oxidation were then calculated by the constants presented by Brouwer. 8 During the entire stays, heart rate and ECG were continuously monitored by a telemetry system (Dialogue 2000, Danica Electronics, Copenhagen, Denmark) and stored in a computer for subsequent analysis. Spontaneous physical activity (SPA) in the respiration chambers was assessed by two microwave radars (Sisor, Mini-Radar, Static Input System S.A., Lausanne, Switzerland), which continuously emit and receive a signal. When the radar detects a moving object a signal is generated and received by the transceiver. Thus the SPA scores represent the percentage of time that the subject performed movements above a detection limit.
During the stays in the chamber, similar activity protocols with ®xed meal time and sessions of physical activity were followed in the two studies. Two (ZD2079 study) or four (ZD7114 study) 10 min bouts of bicycling at 75 W work output were included in the protocol. To ensure adherence to the protocol the subjects were kept under constant surveillance by a laboratory technician during the day-time and by a trained medical student at night. To accustom the subjects to the environment, they spent the night preceding the experiments in the chamber.
In an attempt to achieve energy balance during the measurements, the energy content of the 24 h experimental diet during the chamber stay in the ZD7114 study was individually calculated from the subjects' . These algorithms were obtained by simple regression analysis on data from a previous study performed with similar protocols at our department. However, the results from the ZD7114 study were used to estimate energy content of the 24 h diet in the subsequent ZD2079 study. The equation 137 kJakgÂFFM 1898 kJ was achieved by a linear regression when all subjects from the ZD7114 study were included. The diet provided 48% and 43% energy from carbohydrate, 37% and 43% energy from fat and 15% and 14% energy from protein in the ZD7114 and ZD2079 studies, respectively, which yielded food quotients (FQ) of 0.853 and 0.837. Dietary energy content and composition were calculated by`DANKOST' dietary assessment software (Danish Catering Center, Denmark), which is based on the Atwater factors for metabolizable energy. Food left-overs were reweighed item for item, and used in the calculation of actual energy and macronutrient intake. Only decaffeinated tea or coffee was allowed in ZD2079. Fasting blood samples were taken in the morning following the end of the respiration chamber stay.
Subjects
All subjects underwent a full medical history and physical examination, electrocardiogram, routine haeEnergy expenditure with ZD7114 or ZD2079 B Buemann et al matology and biochemistry and urine screening tests, and were found to be in good health apart from obesity without previous or present endocrine, cardiovascular or hepatic diseases. Furthermore, the subjects did not report any acute illness within 2 weeks of the start of the trial. None of the subjects were dieting or took any regular medication, with the exception of one female who was taking diuretics. They had all been weight stable ( AE 3 kg) for at least 3 months prior to the study. In connection with the screening visit all subjects were carefully instructed how to maintain their body weight to prevent large weight excursions during the study but no other measures were taken to ensure weight stability. During the treatment period between the two calorimetry measurements no particular restrictions were imposed on the subjects except that no more than two units of alcohol should be consumed per day and that no other medication must be taken unless considered absolutely necessary. They were instructed to report any additional medical use during this period to the investigator. Finally smoking was not allowed during and 12 h preceding each respiration chamber stay. All females were postmenopausal in both studies to eliminate the in¯uence of the menstrual cycle on EE and other measured variables. Both studies were approved by the Ethics Commitee of Frederiksberg and Copenhagen and the subjects gave informed consent according to the declaration of Helsinki II.
Design
Before and at the end of the treatment period body weight was measured in light clothing on a decimal scale (Seca model 707, Copenhagen) shortly prior to the indirect calorimetry experiments. At the same time body composition was estimated by a bioelectrical impedance method using an Animeter (HTS-Engineering Inc., Odense, Denmark). Fat-free mass (FFM) and fat-mass (FM) were calculated by an algorithm presented by Heitmann. 9 In the ZD7114 study waist and hip circumferences were measured as described by Lohman. 10 As a marker for a possible b 2 -activity, fasting blood was analysed for serum potassium concentration before the initiation of the therapy and on the 4th or 5th day after the ®rst day of administration. In the ZD7114 study we also performed an 180 min oral glucose tolerance test (OGTT) with 75 g glucose after an overnight fast before and at the end of the treatment period to test if the compound may improve glucose tolerance. The genders were allocated separately in both studies to achieve a balanced sex distribution.
ZD7114 study. Nine male and 16 female subjects were included and randomized to doses of 50 or 100 mg three times daily or to placebo. There were two drop-outs in the 50 mg group during the trial, one female due to in¯uenza, and one male due to epidydimitis following a vasectomy. A third subject was excluded from the study after allocation as he had NIDDM diagnosed at the ®rst OGTT test. Physical characteristics of the groups obtained the day before and on the last day of the treatment period are listed in Table 1 .
ZD2079 study. The subjects were randomized to a 600 mg dose twice daily or placebo. Ten male and seven female subjects completed the study but one subject in the placebo group withdrew after allocation due to a tentative diagnosis of ulcerous colitis. The physical characteristics of the groups are listed in Table 2 .
In this study, the 24 h measuring period was subdivided into 4 h intervals to detect possible effects of the agent related to particular periods of the day.
Statistics
The effects of the two agents were tested by comparing observations during treatment with baseline data using repeated measures ANOVA with treatment group entered as a between-subject factor. As SPA differed with borderline signi®cance from baseline to day 14 in the ZD2079 study, the analyses on EE and HR were repeated with SPA included as a covariate. As body weight or FFM were similar across the treatment periods these factors were not included in the analyses. The analyses were performed with SPSS 9.0 for Windows (SPSS Inc., Chicago, IL).
Results
Weight stability was successfully achieved during the treatment period in both studies and weight and body composition seemed unaffected by the compounds (Tables 3 and 4 ). In the D7117 study where the waist and hip circumferences were measured, no effect of the agent was found (Table 3) . Twenty-four hour and sleeping EE and respiratory quotient were similar before and on day 14 of the ZD7114 medication with either doses (Table 5) . A borderline signi®cant increasing effect on 24 h EE of ZD2079 was found (Table 6 ). However, 24 h spontaneous physical activity (SPA) also tended to be positively in¯uenced by ZD2079, and pre-treatment to day 14 changes in SPA positively correlated with the corresponding change in 24 h EE (r 0.62, P`0.01). For these reasons, the trend to an effect on EE of the compound disappeared when SPA was included in the analysis as a covariate (Table 6 ). When each of the 4 h measuring periods were tested no effect of ZD2079 was detected. No acute effect on EE was found of either compound when the 4 h morning period during baseline measurements was compared with the 4 h period after the ®rst dose on the subsequent morning (meanAE s (Tables 5 and 6 ) and 24 h protein oxidation expressed as percent of the total oxidation was unaffected by either compound (meanAE s.e.m.: ZD7114, baseline vs placeboÂbase-line vs 300 mgaday: 13.6AE 0.9 vs 14.5AE 0.9 Â14.2 AE 0.9 vs 13.6 AE 0.9%, P 0.34 for drugÂtime interaction; ZD2079, baseline vs placeboÂbaseline vs 1200 mgaday: 14.9 AE 0.8 vs 15.5 AE 0.7Â16.5AE 0.8 vs 16.3 AE 0.7%, P 0.53 for drugÂtime interaction). In the ZD7114 study where OGTTs were performed, no difference between the treatment groups was detected in the pre-to post-treatment changes of the incremental areas under curve (AUC) of the glucose response (absolute AUC day 15 minus baseline, 300 mgaday vs placebo: 7 29.9 AE 66.1 vs 15.5 AE 52.8 min*mmolal, P 0.60). ZD7114 did not signi®-cantly affect 24 h heart rate ( Table 7) whereas ZD2079 increased heart rate relative to the placebo treatment. This effect was seen as a maintained heart rate from the baseline to day 14 when the active agent was administered while heart rate declined (P`0.005) with placebo. A trend of a positive effect of the compound on heart rate persisted after changes in SPA were accounted for (Table 8) . Serum potassium concentration tended to be increased rather than reduced with ZD2079 as otherwise would be expected if the compound had possessed a b 2 -activity and ZD7114 did not seem to affect serum potassium (Tables 7 and 8 ).
Discussion
The lack of effect of ZD7114 on 24 h EE and substrate partitioning and on sleeping EE in the present study with obese subjects is in line with an experiment using a similar protocol where a daily dose of 150 mgaday ZD7114 was administered to normal weight men. 11 These results are in contrast to the marked acute thermogenic effect of the compound both in dogs and rats at a dose of 0.1 mgakg body weight. 6 The ED 50 dose for the thermogenic effect of ZD7114 in rats was 0.04 mgakg body weight whereas 1.0 mgakg was required to achieve a detectable increase in heart rate. With the unselective b-agonist isoprenaline a marked increase in heart rate is observed in rats at the ED 50 dose for its thermogenic effect. 6 This demonstrates the selectivity of the ZD7114's b-activity in rats to increase EE. Furthermore, b 3 -agonistic capacity of ZD7114 has previously been demonstrated in rats by an increased mitochondrial guanosine diphosphate (GDP) binding in brown adipocytes which represents a marker of b 3 -stimulation. 6 Moreover, the acid metabolite of ZD7114 has been shown to be a partial lipolytic agonist in isolated white rat adipocytes. 12 The lack of thermogenic ef®cacy of ZD7114 in humans must therefore be explained by species variation in the b 3 -receptor or by lack of suf®cient tissue in humans that can elicit a b 3 -receptor mediated thermogenic response.
A marginal effect of ZD2079 on 24 h EE was found at the end of the 14-day treatment period compared to baseline measurements. The 600 mg dose of ZD2079 was chosen on the basis of previous results in humans showing a 10.5% increase in resting oxygen consumption between 1.5 and 2.5 h after a single dose of this size (unpublished results). The more modest and insigni®cant 24 h response in the present study may be explained by a fast post-dose decline in the thermogenic effect of the agent and random variation caused by the subjects' spontaneous activity in the chamber. In rat white adipocytes ZD2079 has been found to be a full agonist on lipolysis relatively to isoprenaline, 13 whereas ZD7114 was reported only to be a partial agonist in the same model. 14 However, tests with human b 3 -receptor transfected chinese hamster ovary (CHO) cells showed a lower sensitivity for the stimulation of adenyl cyclase with ZD2079 (K act 191 nM) than with ZD201651 (K act 20 nM) which is the major metabolite of ZD7114. In the present studies, the daily dose of ZD2079 (in g) was only four times higher than the highest daily dose of ZD7114.
When tested on human b 2 receptor transfected CHO cells some agonistic activity of ZD2079 was detected despite the fact that no b 2 activity based on serum 13 Accordingly, no decline in serum potassium was observed with ZD2079 in the present study. However, an acute reduction in potassium might have been over-looked as serum potassium tends to return to normal after adaptation to b 2 adrenergic stimulation. 15 The signi®cant chronotropic effect of ZD2079 found in the present study is in line with the previously reported increase in heart rate during exercise after administration of the agent 16 and suggests some b 1 -activity in humans. However, it cannot be excluded that the increased heart rate could be secondary to a vasodilatation caused by the b 3 -stimulation. Increased cutaneous blood¯ow has been reported in dogs after administration of b 3 -agonists, 17 however, there were no complaints of skin¯ushing during our experiments. Induction of an increased nutritive blood¯ow to other tissues by b 3 stimulation as a consequence of an increased metabolic rate or lipolytic activity cannot be excluded to occur also in man.
Parallel to the increasing effect of ZD2079 on 24 h EE we found a borderline signi®cant positive impact on 24 h SPA. There are no obvious explanations for this apparent stimulation of motor activity but central effects cannot be excluded as intraventricular noradrenaline infusion increases physical activity in rodents, 18 whereas centrally but not exclusively peripherally acting b-antagonists have a sedentary effect. 19 Although the statistical trend of an increased 24 h EE with ZD2079 disappeared after the inclusion of SPA as covariate we are not able to conclude whether the possible thermogenic effect may be entirely attributable to more ®dgeting as the extra energy requirement cannot be quanti®ed because we only performed qualitative recordings of the movements in the chamber.
ZD2079 has been shown to possess the capacity to invoke UCP-1 gene expression in cultured differentiated human adipocytes from different sites, although the amount of mRNA quanti®ed by semi-quantitative RT-PCR was substantially less than could be detected in untreated brown adipocytes retrieved from an infant. 20 Furthermore, experiments in adult dogs have demonstrated a reappearance of brown adipose tissue detected by the presence of UCP-1 after 8 weeks treatment with the b 3 -agonist ZD7114. 21 It may therefore be speculated that b 3 -agonists may exert a thermogenic effect by the promotion of UCP-1 gene expression also in humans.
No effect was found on 24 h substrate partitioning represented by RQ or non-protein RQ of either of the two b 3 -agonists tested in the present studies. In vitro studies on human adipocytes or adipose tissue suggest that omental 22 but not subcutaneous 23 fat has a signi®cant lipolytic responsiveness to b 3 -adrenergic stimulation. Furthermore, in rodents b 3 -adrenergic stimulation seems to promote fat oxidation beyond what can be explained by an augmented release of FFA, as 20 days treatment with the b 3 -agonsist BRL-35135 lowers plasma FFA concentration both in lean and obese obaob mice accompanied by an increased brown adipose tissue mass. 24 A human study with the b 3 -agonist Ro 16-8714 found no effect on RQ of the agent within a 6 h post-dosing period despite a signi®cant increase in EE and plasma FFA being observed. 25 This suggests that even compounds which show b 3 -adrenergic ef®cacy in man do not necessarily increase relative fat oxidation acutely.
Until now, only a few other studies have been conducted to test the thermogenic potential of treatment with b 3 -agonists in humans. In one study with BRL 26830A, an increased weight loss accompanied by a diminished drop in RMR was reported during a hypoenergetic diet 26 but tremors were also observed, which suggests that the compound had some b 2 -activity which could explain part of its thermogenic effect. The agent Ro 40-2148 showed no haemodynamic effects when administered to obese women but increased glucose-induced thermogenesis after 14 days' treatment. 27 However, no effect was found on baseline RMR in contrast to the thermogenic effect of the compound previously observed in rodents. 28 Another b 3 -adrenergic agent, Ro16-8714 showed a substantial effect on fasting metabolic rate in man but the compound increased heart rate disproportionally to the rise in EE, which indicated that b 1 -adrenergic properties may have accounted for a part of its thermogenic effect. Along with their thermogenic effects, b 3 -agonists may improve glucose tolerance, an effect which has also been reported from treatment studies in obese humans. 29 We found no effect of ZD7114 on glucose tolerance which, in fact, was in line with the other absent effects of the agent.
The dissatisfying outcome of the studies conducted so far on the thermogenic effects of b 3 -adrenergic agents in humans may relate to species dissimilarities of the receptors. The human and rodent b 3 receptors have 80 ± 90% amino acid sequence homology and the homology is particularly great within the functional domains of the protein. 30 Furthermore, when af®nity and activity properties to different compounds are tested in CHO cells transfected with cloned rat or human b 3 -receptor there are great pharmacological similarities. 30 However, in this model, the b 3 -sensitivity to particular compounds assessed by the activation of adenyl cyclase has shown some variations. In this context, BRL34377 was found to be 15 times more potent when the CHO cells were tranfected with the rat compared to the human b 3 -receptor, though the sensitivity to isoprenaline was similar between the two cell lines. 31 The authors speculated that the af®nity to some arti®cial b 3 -agonists may be in¯u-enced by the structure of special binding sites which have been less evolutionarily conserved. Moreover, even agents which show a high b 3 -potency to human b 3 -adrenoceptors tranfected CHO cells, may fail to be ef®cient in in vivo experiments exempli®ed by the lack of thermogenic effect of ZD7114 in the present study despite the fact that ZD201651, which is the in Energy expenditure with ZD7114 or ZD2079 B Buemann et al vivo metabolized form of ZD7114, has been reported to be a strong activator of adenyl cyclase in the transfected CHO cell model. 32 The poor human b 3 -adrenergic potency of ZD7114 has also been demonstrated by an experiment where ZD7114 was added to isolated human omental adipocytes. 33 The discrepancies both at in vivo and in vitro experiments between the poor or absent b 3 -responsiveness to ZD7114 observed in human models and the more signi®cant responses seen in rats questions a general applicability of non-primate models to elucidate the b 3 -adrenergic potency of speci®c agents in humans.
In conclusion, in the present studies no statistically signi®cant effects on oxidative metabolism of the two tested agents could be demonstrated in man although they previously have been found to be b 3 -agonists in other species. There was a trend for ZD2079 to stimulate EE accompanied by an effect on physical activity. The doses for both compounds in the present tests were chosen at a level where no or little side effects due to unspeci®c b-adrenergic stimulation would be expected according to previous tests. More investigations may be relevant with higher doses, particularly with ZD2079, to clarify if a therapeutic window may exist. Furthermore, the two drugs were tested during weight maintenance and a more obvious thermogenic effect of these b 3 -agonists might have appeared during a hypoenergetic regimen where the endogenous b-adrenergic activity may be suppressed. In the future, selective b 3 -agonists with a higher ef®cacy in humans may be developed and these agents may con®rm or refute the possibility that a pronounced thermogenic response can be achieved in man with b 3 -adrenergic agents without adverse sideeffects.
